溶瘤腺病毒及其靶向治疗肿瘤研究进展  

Oncolytic adenovirus in tumor targeted therapy

作　　者：胡建鹏(综述)[1] 郝林(综述)[1] 韩从辉(审校)[1] 

机构地区：[1]东南大学医学院附属徐州医院泌尿外科东南大学临床医学院,221009

出　　处：《国际肿瘤学杂志》2009年第11期815-818,共4页Journal of International Oncology

基　　金：国家自然科学基金项目（30973443）;江苏省自然科学基金项目（BK2009085）

摘　　要：溶瘤腺病毒是对已知腺病毒进行改造得到的能对肿瘤基因表型的缺陷产生特异性杀伤作用及起到抗肿瘤药物的靶向性载体作用的病毒。目前通过对腺病毒5的特定基因片段的处理得到了H101和d11520等生物制品，针对肿瘤细胞的p53基因表达缺陷，特异性识别肿瘤并在肿瘤细胞内进行繁殖和裂解肿瘤细胞。这些生物制品可以作为载体携带抗肿瘤基因，产生更加强大的抗肿瘤作用。Oncolytic adenovirus is known to carry out the transformation of adenovirus,which has killing role on tumor defective gene phenotypes, and can be used as vector for tumor targeted therapy drugs. At present, HI01 and dl1520 and other biological products are gained from adenovirus type 5-specific gene fragments, which targeted tumor cell defects in the p53 gene expression, can specifically recognize tumor cells and carry, out proliferation and lysis of tumor cells. These biological products can be used as vectors to carry the anti-tumor genes and result in more powerful anti-tumor effects.

关 键 词：溶瘤病毒 肿瘤 

分 类 号：R730.5[医药卫生—肿瘤] R979.1[医药卫生—临床医学]